FindTrial
Sign In

exploration of the association of androgen receptor expression with the survival outcomes of premenopausal hormone receptor positive early stage breast cancer undergoing ovarian suppression and aromatase inhibitor

exploration of the association of androgen receptor expression with the survival outcomes of premenopausal hormone receptor positive early stage breast cancer undergoing ovarian suppression and aromatase inhibitor

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000035763
Enrollment
Unknown
Registered
2020-08-16
Start date
2020-10-01
Completion date
Unknown
Last updated
2020-08-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

breast cancer

Interventions

Case series:OFS+AI

Sponsors

Obstetrics and Gynecology Hospital of Fudan University
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: 1. female, premenopausal, aged under 45 years; 2. pathological confirmed invasive breast cancer, TNM stage:T1-2N0-micM0; 3. IHC confirmed ER>50% + and FISH confirmed HER2; 4. undergoing mastectomy or breast conserving surgery, SLNB or ALND; 5. 21 gene recurrence score 11-25; 6. normal blood routine, liver and renal function; 7. ECOG 1-2; 8. not pregnant during treatment and hCG - before treatment; 9. well cooperated and informed consented.

Exclusion criteria

Exclusion criteria: 1. distant metastasis at diagnosis; 2. Dexamethasone allergy or other serious allergy; 3. serious cardiovascular, pulmonary, liver, renal, nervous, or psychiatry disease; 4. pregnancy or lactation.

Design outcomes

Primary

MeasureTime frame
DFS;—

Countries

China

Contacts

Public ContactChen Hongliang

Obstetrics and Gynecology Hospital of Fudan University

13671852284@163.com+86 13671852284

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026